Assignee
ASTEX THERAPEUTICS LTD
GB·67 granted patents·49 pending applications·651 citations·filing 2003–2024
Top patents by PatentIndex Score
116 records- 0196US7754725B2Dihydroxyphenyl isoindolymethanonesASTEX THERAPEUTICS LTD·Filed 2007·Granted Jul 13, 2010·22 cites·10 claims
- 0295US10544132B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 28, 2020·10 cites·27 claims
- 0395US9850228B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Dec 26, 2017·17 cites·5 claims
- 0495US9464071B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 11, 2016·24 cites·45 claims
- 0595US9458158B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Oct 4, 2016·11 cites·22 claims
- 0695US9447098B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2013·Granted Sep 20, 2016·35 cites·20 claims
- 0795US7385059B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2006·Granted Jun 10, 2008·33 cites·20 claims
- 0894US9309242B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 12, 2016·26 cites·28 claims
- 0994US9303029B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 5, 2016·25 cites·20 claims
- 1094US9303030B2CompoundsASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 5, 2016·26 cites·21 claims
- 1194US7700625B2Hydroxybenzamide derivatives and their use as inhibitors of Hsp90ASTEX THERAPEUTICS LTD·Filed 2007·Granted Apr 20, 2010·25 cites·10 claims
- 1293US11225476B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 18, 2022·3 cites·13 claims
- 1393US9856236B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2015·Granted Jan 2, 2018·16 cites·20 claims
- 1493US9737544B2CompoundsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 22, 2017·15 cites·20 claims
- 1593US9439896B2Quinolines as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2012·Granted Sep 13, 2016·22 cites·20 claims
- 1692US11866428B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2020·Granted Jan 9, 2024·2 cites·21 claims
- 1792US10981898B2Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Apr 20, 2021·4 cites·27 claims
- 1892US10526311B2Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 7, 2020·6 cites·25 claims
- 1992US10052320B2Substituted quinoxalines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 21, 2018·11 cites·20 claims
- 2092US10045982B2Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 14, 2018·11 cites·33 claims
- 2192US10039759B2Quinolines as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Aug 7, 2018·11 cites·21 claims
- 2292US9617248B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 11, 2017·10 cites·20 claims
- 2392US9527844B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2015·Granted Dec 27, 2016·20 cites·16 claims
- 2492US9493426B2Quinazolinone derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2014·Granted Nov 15, 2016·20 cites·20 claims
- 2591US9980973B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted May 29, 2018·6 cites·21 claims
- 2691US9902714B2Quinoxaline derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2015·Granted Feb 27, 2018·15 cites·22 claims
- 2791US9783538B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2014·Granted Oct 10, 2017·12 cites·53 claims
- 2891US9757364B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2016·Granted Sep 12, 2017·15 cites·21 claims
- 2991US9309241B2Naphthyridine derivative compoundsASTEX THERAPEUTICS LTD·Filed 2012·Granted Apr 12, 2016·26 cites·17 claims
- 3090US11643410B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2021·Granted May 9, 2023·1 cites·22 claims
- 3190US10519137B2Pyrazolyl quinoxaline kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2017·Granted Dec 31, 2019·6 cites·18 claims
- 3290US10085982B2CombinationsASTEX THERAPEUTICS LTD·Filed 2015·Granted Oct 2, 2018·12 cites·12 claims
- 3390US9676768B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2015·Granted Jun 13, 2017·8 cites·16 claims
- 3490US7977477B2Benzimidazole derivatives and their use as protein kinase inhibitorsASTEX THERAPEUTICS LTD·Filed 2004·Granted Jul 12, 2011·35 cites·23 claims
- 3589US10898482B2Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamineASTEX THERAPEUTICS LTD·Filed 2016·Granted Jan 26, 2021·7 cites·66 claims
- 3689US2025296930A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2024·Application pending·0 cites
- 3788US10716787B2CombinationsASTEX THERAPEUTICS LTD·Filed 2018·Granted Jul 21, 2020·3 cites·13 claims
- 3888US7825140B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Nov 2, 2010·7 cites·19 claims
- 3988US7745638B23,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinase and glycogen synthase kinase-3 modulatorsASTEX THERAPEUTICS LTD·Filed 2007·Granted Jun 29, 2010·8 cites·23 claims
- 4087US10736900B2Combinations of an FGFR inhibitor and an IGF1R inhibitorASTEX THERAPEUTICS LTD·Filed 2015·Granted Aug 11, 2020·4 cites·7 claims
- 4187US10618895B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2017·Granted Apr 14, 2020·4 cites·33 claims
- 4287US10421747B2Quinoxaline derivatives useful as FGFR kinase modulatorsASTEX THERAPEUTICS LTD·Filed 2017·Granted Sep 24, 2019·6 cites·19 claims
- 4386US9617283B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2013·Granted Apr 11, 2017·10 cites·20 claims
- 4486US8383619B2Pharmaceutical compoundsASTEX THERAPEUTICS LTD·Filed 2010·Granted Feb 26, 2013·8 cites·13 claims
- 4585US11261171B1Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activityASTEX THERAPEUTICS LTD·Filed 2019·Granted Mar 1, 2022·2 cites·24 claims
- 4685US10272087B2Pteridines as FGFR inhibitorsASTEX THERAPEUTICS LTD·Filed 2016·Granted Apr 30, 2019·5 cites·21 claims
- 4785US2024199607A1Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2023·Application pending·0 cites
- 4884US12202828B2Bicyclic heterocycle compounds and their uses in therapyASTEX THERAPEUTICS LTD·Filed 2022·Granted Jan 21, 2025·0 cites·48 claims
- 4984US12077526B2Isoindolinone inhibitors of the MDM2-P53 interaction and process for making themASTEX THERAPEUTICS LTD·Filed 2023·Granted Sep 3, 2024·1 cites·22 claims
- 5084US11236047B2Combination of isoindolinone derivatives with SGI-110ASTEX THERAPEUTICS LTD·Filed 2018·Granted Feb 1, 2022·2 cites·21 claims
Showing the top 50 of 116 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ASTEX THERAPEUTICS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →